Netherlands· NL-fb8ef5d07bc7
Rayaldee 30 microgram, zachte capsule met verlengde afgifte
A calcifediol product containing calcifediol 1-water, registered in Netherlands by Vifor Fresenius Medical Care Renal Pharma France. The same ATC class is registered in 6 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Calcifediol is registered in 6 of 19 countries.
Countries holding a registration under ATC H05BX05 (calcifediol), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 2 of them publish a price we can compare per daily dose
Calcifediol · ATC H05BX05
6 / 19 countries
- Denmark
- Germany
- Netherlands
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of calcifediol costs, country by country.
Normalised to the WHO defined daily dose (30 mcg), the median price runs from $0.13 in Spain to $4.51 in Switzerland — a ×34 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Calcifediol · price per daily dose (30 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$4.51
- ES Spain$0.13
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CALCIFEDIOL 1-WATER
- Manufacturer
- Vifor Fresenius Medical Care Renal Pharma France
- Country
- Netherlands (NL)
- ATC code
- H05BX05
- ATC class
- Calcifediol
- Defined daily dose
- 30 mcg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id124799
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
68 interactions on record for calcifediol.
Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Calcifediol · interactions on record
68 records
- 10 severe
- 57 moderate
- 1 minor
Most severe, free to view
- ErgocalciferolA11CC01severe
- DihydrotachysterolA11CC02severe
- CalcitriolA11CC04severe
- ColecalciferolA11CC05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Calcifediol in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesRayaldeeOPKO Pharmaceuticals LLC
- SpainRAYALDEE 30 MICROGRAMOS CAPSULAS BLANDAS DE LIBERACION PROLONGADAVifor Fresenius Medical Care Renal Pharma France
- SwedenRayaldee 30 mikrogram Depotkapsel, mjukVifor Fresenius Medical Care Renal Pharma France
- CzechiaUPEROLDBERLIN-CHEMIE AG, Berlín
- PolandCalfosAllpharm Sp. z o.o. sp.k.
- FranceCALCIFEDIOL DESMA 15 mg/100 ml, solution buvable en gouttesDESMA PHARMA
- ItalyDIDROGYLBRUNO FARMACEUTICI S.P.A.
- BelgiumDedrogyl 0.15 mg/mlLaboratorio Farmaceutico S.I.T.
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Hidroferol
- Belgium · Dédrogyl, Defediol
- Bulgaria · Хидроферол
- Czechia · Uperold
- Germany · Dedrogyl, Rayaldee
- Denmark · Defevix, Rayaldee
- Estonia · Defevix, Hidrosun
- Spain · Calcifediol Normogen, Calcifediol Normon
- Finland · Defevix
- France · Calcifediol Desma, Calcifediol Gerda
- United Kingdom (Northern Ireland) · Domnisol
- Greece · D Ready, Hidroferol
- Croatia · Defevix, Tryde
- Hungary · Defevix
- Ireland · Calcifediol Faes, Dnord
- Italy · Didrogyl, Hercal
- Lithuania · Calcifediol Faes, Defevix
- Luxembourg · Defediol, Hidroferol Hebdomadaire
- Latvia · Defevix
- Norway · Defevix, Hidrosun
- Poland · Calfos, Devisol-25
- Portugal · Dedrogyl, Dvit
- Romania · Hidroferol
- Sweden · Defevix, Rayaldee
- Slovenia · Defevix, Kalcifediol Faes
- Slovakia · Defevix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c1bd0563-7ba8-48d0-a958-c215779cf2f1 GET /v1/drugs/c1bd0563-7ba8-48d0-a958-c215779cf2f1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule met verlengde afgifte, zacht",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h124799_smpc.pdf",
"strength": null,
"atc_label": "Calcifediol",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg124799",
"excipients": [
"BRILJANTBLAUW FCF (E 133)",
"BUTYLHYDROXYTOLUEEN (E 321)",
"CARRAGEENAN (E 407)",
"DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
"ETHANOL",
"GLYCEROLMONOSTEARAAT 40-55 (E 471)",
"HYPROMELLOSE (E 464)",
"HYPROMELLOSE 2208 (Release controlling polymer), K100M (E 464)",
"LAUROYLMACROGOLGLYCERIDEN",
"MAÏSZETMEEL, GEMODIFICEERD",
"PARAFFINE, HARD (E 905)",
"PARAFFINE, VLOEIBAAR (E905)",
"PROPYLEENGLYCOL (E 1520)",
"SORBITOL VLOEIBAAR, GEDEELTELIJK GEDEHYDRATEERD",
"TITAANDIOXIDE (E 171)",
"TITAANDIOXIDE (E 171)",
"TRIGLYCERIDEN MIDDELLANGE KETEN",
"WATER, GEZUIVERD",
"WITTE INKT"
],
"substances": [
"CALCIFEDIOL 1-WATER"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h124799.pdf",
"authorised_at": "2020/09/22",
"procedure_number": "DE/H/5590/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "124799",
"additional_monitoring": "N"
}See everything about calcifediol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.